Useful in situations where identity or class of the drug or drugs of interest is not known. Not recommended for assessment in routine compliance and/or abuse contexts.
Qualitative Immunoassay/Gas Chromatography-Mass Spectrometry/Liquid Chromatography-Tandem Mass Spectrometry
Fresh random urine.
Transport 25 mL urine. (Min: 12 mL)
Ambient: 5 days; Refrigerated: 2 weeks; Frozen: 2 months
The following drugs or drug classes may be detected:
Acetaminophen, barbiturates, benzodiazepines, carbamazepine, carisoprodol, chlorpheniramine, cocaine and metabolites, diphenhydramine, ethchlorvynol, ibuprofen, lidocaine, meprobamate, narcotics and synthetics, phencyclidine, phenothiazines, phenytoin, primidone and metabolites, pyrilamine, salicylate, sympathomimetic amines, theophylline, tricyclic and other antidepressants.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
This test is not optimized for most drugs of abuse (amphet/methamphet, barbiturates, benzodiazepines, cocaine, methadone, opiates, propoxyphene, PCP, THC); instead refer to Drug Panel 9, Urine - Screen with Reflex to Confirmation/Quantitation (ARUP test code 0092186), Drug Panel 7, Urine - Screen with Reflex to Confirmation/Quantitation (ARUP test code 0092184).
|Component Test Code*||Component Chart Name||LOINC|
|0090500||Drug Screen (Nonforensic), Urine, Qual||12286-1|
- Carisoprodol Screen with Reflex Confirmation
- Drug Analysis
- Multiple Drug Analysis
- Tox Screen Urine
- Urine Drug Screen